ducovest

SCPS:OTC-Scopus Biopharma Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.0003

Change

0.00 (0.00)%

Market Cap

USD 0.01M

Volume

425.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.

Company Website : https://scopusbiopharma.com

Currency: USD

Country : USA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
ARGNF argenx SE

N/A

 USD 42.54B
UCBJY UCB SA ADR

N/A

 USD 33.33B
UCBJF UCB SA

N/A

 USD 33.33B
GNMSF Genmab A/S

N/A

 USD 12.13B
IVBIY IVBIY

N/A

 USD 10.52B
WXXWY WuXi Biologics (Cayman) Inc

N/A

 USD 10.47B
WXIBF WuXi Biologics

N/A

 USD 10.43B
AKESF Akeso, Inc.

N/A

 USD 9.51B
SBMFF Sino Biopharmaceutical Limited

N/A

 USD 9.09B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

 USD 9.09B

ETFs Containing SCPS

IEO iShares U.S. Oil & Gas Ex.. 19.83 % 0.42 %

N/A

 USD 0.34B
NRGU Bank of Montreal 10.25 % 0.00 %

N/A

 N/A
IS0D:F iShares Oil & Gas Explora.. 10.05 % 0.00 %

N/A

 N/A
IS0D:XETRA iShares Oil & Gas Explora.. 10.05 % 0.00 %

N/A

 N/A
NRGO 10.00 % 0.00 %

N/A

 N/A
NRGZ 10.00 % 0.00 %

N/A

 N/A
YGRN 10.00 % 0.00 %

N/A

 N/A
IOGP:LSE iShares Oil & Gas Explora.. 9.79 % 0.00 %

N/A

 N/A
SPOG:LSE iShares V Public Limited .. 9.76 % 0.00 %

N/A

 N/A
FRAK 8.73 % 0.54 %

N/A

 N/A
FTXN First Trust Nasdaq Oil & .. 8.14 % 0.60 %

N/A

 USD 0.16B
SXLE:LSE SPDR S&P U.S. Energy Sele.. 7.68 % 0.00 %

N/A

 N/A
ZPDE:F SPDR S&P U.S. Energy Sele.. 7.68 % 0.00 %

N/A

 USD 0.78B
ZPDE:XETRA SPDR® S&P® U.S. Energy .. 7.68 % 0.00 %

N/A

 N/A
XSEN:LSE db x-trackers MSCI USA En.. 7.51 % 0.00 %

N/A

 USD 0.08B
XUEN:LSE db x-trackers MSCI USA En.. 7.51 % 0.00 %

N/A

 USD 0.08B
XUEN:F Xtrackers (IE) Public Lim.. 7.51 % 0.00 %

N/A

 USD 0.09B
XUEN:XETRA db x-trackers MSCI USA En.. 7.51 % 0.00 %

N/A

 N/A
IESU:LSE iShares S&P 500 Energy Se.. 7.47 % 0.00 %

N/A

 N/A
OILD MicroSectorsTM Oil & Gas .. 7.40 % 1.24 %

N/A

 USD 0.02B
OILU MicroSectorsTM Oil & Gas .. 7.40 % 1.22 %

N/A

 USD 0.03B
IUES:LSE iShares S&P 500 Energy Se.. 7.40 % 0.00 %

N/A

 USD 0.81B
IUSE:LSE iShares S&P 500 EUR Hedge.. 7.40 % 0.00 %

N/A

 USD 6.66B
QDVF:F iShares S&P 500 Energy Se.. 7.40 % 0.00 %

N/A

 N/A
QDVF:XETRA iShares S&P 500 Energy Se.. 7.40 % 0.00 %

N/A

 N/A
IYE iShares U.S. Energy ETF 7.17 % 0.42 %

N/A

 N/A
JHME 6.90 % 0.48 %

N/A

 N/A
NXF-B:CA CI Energy Giants Covered .. 6.75 % 0.00 %

N/A

 CAD 0.02B
ERX Direxion Daily Energy Bul.. 6.61 % 1.08 %

N/A

 N/A
DIG ProShares Ultra Oil & Gas 6.04 % 0.95 %

N/A

 N/A
DDG 5.83 % 0.95 %

N/A

 N/A
DUG ProShares UltraShort Oil .. 5.83 % 0.95 %

N/A

 N/A
HPF-U:CA Harvest Energy Leaders Pl.. 4.99 % 0.00 %

N/A

 N/A
WNRG:LSE SPDR MSCI World Energy UC.. 4.84 % 0.00 %

N/A

 N/A
XDW0:LSE db x-trackers MSCI World .. 4.84 % 0.00 %

N/A

 N/A
XDW0:F Xtrackers (IE) Public Lim.. 4.84 % 0.00 %

N/A

 USD 1.07B
XDW0:XETRA db x-trackers MSCI World .. 4.84 % 0.00 %

N/A

 N/A
ERYY 4.79 % 0.45 %

N/A

 N/A
FCG First Trust Natural Gas E.. 4.64 % 0.60 %

N/A

 N/A
5MVW:XETRA iShares MSCI World Energy.. 4.53 % 0.00 %

N/A

 N/A
HUL-U:CA 4.46 % 0.00 %

N/A

 N/A
HUL:CA 4.46 % 2.20 %

N/A

 N/A
GASX 4.29 % 1.01 %

N/A

 N/A
IXC iShares Global Energy ETF 4.28 % 0.46 %

N/A

 N/A
IGE iShares North American Na.. 4.20 % 0.46 %

N/A

 N/A
NANR SPDR S&P® North American.. 3.23 % 0.35 %

N/A

 N/A
HEA-U:CA 2.61 % 0.00 %

N/A

 N/A
RFFC RiverFront Dynamic US Fle.. 2.11 % 0.52 %

N/A

 USD 0.03B
SPGP Invesco S&P 500 GARP ETF 2.09 % 0.36 %

N/A

 USD 2.81B
GASL 1.45 % 1.19 %

N/A

 N/A
TERM 0.88 % 0.64 %

N/A

 N/A
JPGL:XETRA JPM Global Equity Multi-F.. 0.34 % 0.00 %

N/A

 N/A
JPGL:LSE JPM Global Equity Multi-F.. 0.34 % 0.00 %

N/A

 USD 0.19B
JPGL:F JPmorgan ETFs Ireland Ica.. 0.34 % 0.00 %

N/A

 N/A
SCHJ Schwab 1-5 Year Corporate.. 0.09 % 0.00 %

N/A

 N/A
BWX SPDR® Bloomberg Internat.. 0.00 % 0.50 %

N/A

 N/A
EBND SPDR® Bloomberg Emerging.. 0.00 % 0.41 %

N/A

 N/A
EQWL Invesco S&P 100 Equal Wei.. 0.00 % 0.25 %

N/A

 N/A
ILF iShares Latin America 40 .. 0.00 % 0.48 %

N/A

 N/A
JPUS JPMorgan Diversified Retu.. 0.00 % 0.19 %

N/A

 USD 0.40B
MTUM iShares MSCI USA Momentum.. 0.00 % 0.15 %

N/A

 USD 3.60B
RYE 0.00 % 0.40 %

N/A

 N/A
WIP SPDR® FTSE International.. 0.00 % 0.50 %

N/A

 N/A
XMEM:LSE Xtrackers MSCI Emerging M.. 0.00 % 0.00 %

N/A

 N/A
XMMD:LSE Xtrackers - MSCI Emerging.. 0.00 % 0.00 %

N/A

 N/A
DBPD:F Xtrackers - ShortDAX x2 D.. 0.00 % 0.00 %

N/A

 N/A
NRGD Bank of Montreal 0.00 % 0.00 %

N/A

 N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain -81.25% 25% F 8% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -81.25% 25% F 8% B-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -75.53% N/A F N/A F
Dividend Return -75.53% N/A F N/A F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 35.00% 81% B- 64% D
Risk Adjusted Return -215.82% 1% F N/A F
Market Capitalization 0.01M 10% F 5% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.